Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 637
Filter
1.
JAMA Health Forum ; 5(4): e235397, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38669033

ABSTRACT

This cross-sectional study compared the characteristics of 340B hospitals that did not receive a lump sum payment with hospitals in the program that did receive payment.


Subject(s)
Medicare Part B , United States , Humans , Medicare Part B/economics , Medicare Part B/legislation & jurisprudence , Hospitals
2.
JAMA ; 329(15): 1283-1289, 2023 04 18.
Article in English | MEDLINE | ID: mdl-37071095

ABSTRACT

Importance: The Inflation Reduction Act of 2022 authorizes Medicare to negotiate prices of top-selling drugs based on several factors, including therapeutic benefit compared with existing treatment options. Objective: To determine the added therapeutic benefit of the 50 top-selling brand-name drugs in Medicare in 2020, as assessed by health technology assessment (HTA) organizations in Canada, France, and Germany. Design, Setting, and Participants: In this cross-sectional study, publicly available therapeutic benefit ratings, US Food and Drug Administration documents, and the Medicare Part B and Part D prescription drug spending dashboards were used to determine the 50 top-selling single-source drugs used in Medicare in 2020 and to assess their added therapeutic benefit ratings through 2021. Main Outcomes and Measures: Ratings from HTA bodies in Canada, France, and Germany were categorized as high (moderate or greater) or low (minor or no) added benefit. Each drug was rated based on its most favorable rating across countries, indications, subpopulations, and dosage forms. We compared the use and prerebate and postrebate (ie, net) Medicare spending between drugs with high vs low added benefit. Results: Forty-nine drugs (98%) received an HTA rating by at least 1 country; 22 of 36 drugs (61%) received a low added benefit rating in Canada, 34 of 47 in France (72%), and 17 of 29 in Germany (59%). Across countries, 27 drugs (55%) had a low added therapeutic rating, accounting for $19.3 billion in annual estimated net spending, or 35% of Medicare net spending on the 50 top-selling single-source drugs and 11% of total Medicare net prescription drug spending in 2020. Compared with those with high added benefit, drugs with a low added therapeutic rating were used by more Medicare beneficiaries (median 387 149 vs 44 869) and had lower net spending per beneficiary (median $992 vs $32 287). Conclusions and Relevance: Many top-selling Medicare drugs received low added benefit ratings by the national HTA organizations of Canada, France, and Germany. When negotiating prices for these drugs, Medicare should ensure they are not priced higher than reasonable therapeutic alternatives.


Subject(s)
Drug Costs , Medicare Part B , Medicare Part D , National Health Programs , Patents as Topic , Prescription Drugs , Cross-Sectional Studies , Drug Costs/legislation & jurisprudence , Drugs, Generic , Health Expenditures , Medicare Part B/economics , Medicare Part B/legislation & jurisprudence , Medicare Part D/economics , Medicare Part D/legislation & jurisprudence , National Health Programs/economics , National Health Programs/legislation & jurisprudence , Prescription Drugs/economics , United States , Canada , France , Germany
5.
Fed Regist ; 83(216): 55626-32, 2018 Nov 07.
Article in English | MEDLINE | ID: mdl-30456937

ABSTRACT

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) changed the modified adjusted gross income (MAGI) ranges associated with Medicare Part B and Medicare prescription drug coverage premiums for years beginning in 2018. The Bipartisan Budget Act of 2018 (BBA 2018) revised the MAGI ranges again for years beginning with 2019. We consider a beneficiary's MAGI and tax filing status to determine: The percentage of the unsubsidized Medicare Part B premium that the beneficiary must pay; and the percentage of the cost of basic Medicare prescription drug coverage the beneficiary must pay. This final rule makes our regulations consistent with the MAGI ranges specified by MACRA and BBA 2018.


Subject(s)
Income , Insurance, Pharmaceutical Services/economics , Medicare Part B/economics , Humans , Insurance, Pharmaceutical Services/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , United States
6.
Fed Regist ; 83(161): 42037-43, 2018 Aug 20.
Article in English | MEDLINE | ID: mdl-30198670

ABSTRACT

This document announces revisions to the Provider Enrollment Moratoria Access Waiver Demonstration (PEWD) for Part B Non-Emergency Ground Ambulance Suppliers and Home Health Agencies. The demonstration was implemented in accordance with section 402(a)(1)(J) of the Social Security Amendments of 1967 and, as revised, gives CMS the authority to grant waivers to the statewide enrollment moratoria on a case-by-case basis in response to access to care issues and previously denied enrollment applications because of statewide moratoria implementation, and to subject providers and suppliers enrolling via such waivers to heightened screening, oversight, and investigations.


Subject(s)
Ambulances/legislation & jurisprudence , Children's Health Insurance Program/legislation & jurisprudence , Home Care Services/legislation & jurisprudence , Medicaid/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Transportation of Patients/legislation & jurisprudence , Fraud/prevention & control , Health Services Accessibility/legislation & jurisprudence , Humans , Pilot Projects , United States
7.
Fed Regist ; 83(149): 37747-50, 2018 Aug 02.
Article in English | MEDLINE | ID: mdl-30074737

ABSTRACT

This document announces the extension of statewide temporary moratoria on the enrollment of new Medicare Part B non-emergency ground ambulance providers and suppliers and Medicare home health agencies and branch locations in Florida, Illinois, Michigan, Texas, Pennsylvania, and New Jersey, as applicable, to prevent and combat fraud, waste, and abuse. This extension also applies to the enrollment of new non- emergency ground ambulance suppliers and home health agencies and branch locations in Medicaid and the Children's Health Insurance Program in those states.


Subject(s)
Ambulances/legislation & jurisprudence , Children's Health Insurance Program/legislation & jurisprudence , Medicaid/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Transportation of Patients/legislation & jurisprudence , Child , Fraud/prevention & control , Humans , United States
8.
Fed Regist ; 83(20): 4147-51, 2018 Jan 30.
Article in English | MEDLINE | ID: mdl-29461022

ABSTRACT

This document announces the extension of statewide temporary moratoria on the enrollment of new Medicare Part B non-emergency ground ambulance providers and suppliers and Medicare home health agencies, subunits, and branch locations in Florida, Illinois, Michigan, Texas, Pennsylvania, and New Jersey, as applicable, to prevent and combat fraud, waste, and abuse. This extension also applies to the enrollment of new non-emergency ground ambulance suppliers and home health agencies, subunits, and branch locations in Medicaid and the Children's Health Insurance Program in those states. For purposes of these moratoria, providers that were participating as network providers in one or more Medicaid managed care organizations prior to January 1, 2018 will not be considered "newly enrolling" when they are required to enroll with the State Medicaid agency pursuant to a new statutory requirement, and thus will not be subject to the moratoria.


Subject(s)
Ambulances/economics , Ambulances/legislation & jurisprudence , Fraud/prevention & control , Home Care Services/economics , Home Care Services/legislation & jurisprudence , Medicaid/economics , Medicaid/legislation & jurisprudence , Medicare Part B/economics , Medicare Part B/legislation & jurisprudence , Child , Child Health Services , Humans , State Government , United States
9.
Fed Regist ; 83(249): 67816-8082, 2018 12 31.
Article in English | MEDLINE | ID: mdl-30596411

ABSTRACT

Under the Medicare Shared Savings Program (Shared Savings Program), providers of services and suppliers that participate in an Accountable Care Organization (ACO) continue to receive traditional Medicare fee-for-service (FFS) payments under Parts A and B, but the ACO may be eligible to receive a shared savings payment if it meets specified quality and savings requirements. The policies included in this final rule provide a new direction for the Shared Savings Program by establishing pathways to success through redesigning the participation options available under the program to encourage ACOs to transition to two-sided models (in which they may share in savings and are accountable for repaying shared losses). These policies are designed to increase savings for the Trust Funds and mitigate losses, reduce gaming opportunities, and promote regulatory flexibility and free-market principles. This final rule also provides new tools to support coordination of care across settings and strengthen beneficiary engagement; and ensure rigorous benchmarking. In this final rule, we also respond to public comments we received on the extreme and uncontrollable circumstances policies for the Shared Savings Program that were used to assess the quality and financial performance of ACOs that were subject to extreme and uncontrollable events, such as Hurricanes Harvey, Irma, and Maria, and the California wildfires, in performance year 2017, including the applicable quality data reporting period for performance year 2017.


Subject(s)
Accountable Care Organizations/economics , Cost Savings/economics , Fee-for-Service Plans/economics , Medicare Part A/economics , Medicare Part B/economics , Medicare/economics , Accountable Care Organizations/legislation & jurisprudence , Benchmarking , Cost Savings/legislation & jurisprudence , Disasters , Fee-for-Service Plans/trends , Forecasting , Health Policy , Humans , Medicare/legislation & jurisprudence , Medicare Part A/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Quality Assurance, Health Care/legislation & jurisprudence , United States
10.
Fed Regist ; 82(219): 52976-3371, 2017 Nov 15.
Article in English | MEDLINE | ID: mdl-29231695

ABSTRACT

This major final rule addresses changes to the Medicare physician fee schedule (PFS) and other Medicare Part B payment policies such as changes to the Medicare Shared Savings Program, to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services, as well as changes in the statute. In addition, this final rule includes policies necessary to begin offering the expanded Medicare Diabetes Prevention Program model.


Subject(s)
Cost Savings/economics , Fee Schedules/economics , Insurance, Health, Reimbursement/economics , Medicare Part B/economics , Medicare/economics , Prospective Payment System/economics , Cost Savings/legislation & jurisprudence , Current Procedural Terminology , Diabetes Mellitus/economics , Diabetes Mellitus/prevention & control , Fee Schedules/legislation & jurisprudence , Humans , Insurance, Health, Reimbursement/legislation & jurisprudence , Medicare/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Prospective Payment System/legislation & jurisprudence , Radiology Information Systems/economics , Radiology Information Systems/legislation & jurisprudence , Relative Value Scales , United States
11.
Fed Regist ; 82(144): 35122-5, 2017 Jul 28.
Article in English | MEDLINE | ID: mdl-28753258

ABSTRACT

This document announces the extension of statewide temporary moratoria on the enrollment of new Medicare Part B non-emergency ground ambulance providers and suppliers and Medicare home health agencies, subunits, and branch locations in Florida, Illinois, Michigan, Texas, Pennsylvania, and New Jersey, as applicable, to prevent and combat fraud, waste, and abuse. This extension also applies to the enrollment of new non-emergency ground ambulance suppliers and home health agencies, subunits, and branch locations in Medicaid and the Children's Health Insurance Program in those states.


Subject(s)
Ambulances/legislation & jurisprudence , Child Health Services/legislation & jurisprudence , Fraud/legislation & jurisprudence , Fraud/prevention & control , Home Care Services/legislation & jurisprudence , Insurance, Health/legislation & jurisprudence , Medicaid/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Child , Florida , Humans , Illinois , Michigan , New Jersey , Pennsylvania , Texas , United States
12.
J Am Coll Radiol ; 14(8): 1007-1012, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28462866

ABSTRACT

PURPOSE: The aim of this study was to assess recent trends in Medicare reimbursements to radiologists, cardiologists, and other physicians for noninvasive diagnostic imaging (NDI). METHODS: The Medicare Part B databases for 2002 to 2015 were the data source. These files provide total allowed payments for all NDI Current Procedural Terminology codes under the Medicare Physician Fee Schedule. Medicare specialty codes were used to identify payments to radiologists, cardiologists, and all other specialists. In additional to total reimbursements, those made for global, technical component, and professional component claims were studied. RESULTS: Total reimbursements to physicians for NDI under the Medicare Physician Fee Schedule peaked at $11.936 billion in 2006. Over the ensuing years, the Deficit Reduction Act and other cuts reduced them by 33% to $8.005 billion in 2015. Reimbursements to radiologists peaked at $5.300 billion in 2006 but dropped to $4.269 billion by 2015 (-19.5%). NDI reimbursements to cardiologists dropped from $2.998 billion in 2006 to $1.653 billion by 2015 (-44.9%). Most other specialties also saw decreases over the study period. An important reason for the large decline for cardiologists was their dependence on global reimbursement, which saw a 50.5% drop from 2006 to 2015. Radiologists' global payments also dropped sharply (40.4%), but radiologists themselves were somewhat protected by receiving a much larger proportion of their reimbursement for the professional component, which was not nearly as affected by Medicare payment reductions. CONCLUSIONS: The Deficit Reduction Act and other NDI payment cuts that followed have created huge savings for the Medicare program but have led to sharp reductions in payments received by radiologists, cardiologists, and other physicians for those services.


Subject(s)
Cardiologists/economics , Medicare Part B/economics , Radiologists/economics , Radiology/economics , Economics, Medical , Fee Schedules , Humans , Medicare Part B/legislation & jurisprudence , Medicare Part B/trends , Medicine , United States
13.
Fed Regist ; 82(1): 180-651, 2017 01 03.
Article in English | MEDLINE | ID: mdl-28071874

ABSTRACT

This final rule implements three new Medicare Parts A and B episode payment models, a Cardiac Rehabilitation (CR) Incentive Payment model and modifications to the existing Comprehensive Care for Joint Replacement model under section 1115A of the Social Security Act. Acute care hospitals in certain selected geographic areas will participate in retrospective episode payment models targeting care for Medicare fee-forservice beneficiaries receiving services during acute myocardial infarction, coronary artery bypass graft, and surgical hip/femur fracture treatment episodes. All related care within 90 days of hospital discharge will be included in the episode of care. We believe these models will further our goals of improving the efficiency and quality of care for Medicare beneficiaries receiving care for these common clinical conditions and procedures.


Subject(s)
Arthroplasty, Replacement, Hip/economics , Cardiac Rehabilitation/economics , Comprehensive Health Care/economics , Episode of Care , Insurance, Health, Reimbursement/economics , Medicare Part A/economics , Medicare Part B/economics , Patient Care Bundles/economics , Reimbursement, Incentive/legislation & jurisprudence , Comprehensive Health Care/legislation & jurisprudence , Coronary Artery Bypass/economics , Coronary Artery Bypass/rehabilitation , Humans , Insurance, Health, Reimbursement/legislation & jurisprudence , Medicare Part A/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Models, Economic , Myocardial Infarction/economics , Myocardial Infarction/rehabilitation , United States
14.
Fed Regist ; 81(220): 80170-562, 2016 Nov 15.
Article in English | MEDLINE | ID: mdl-27906531

ABSTRACT

This major final rule addresses changes to the physician fee schedule and other Medicare Part B payment policies, such as changes to the Value Modifier, to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services, as well as changes in the statute. This final rule also includes changes related to the Medicare Shared Savings Program, requirements for Medicare Advantage Provider Networks, and provides for the release of certain pricing data from Medicare Advantage bids and of data from medical loss ratio reports submitted by Medicare health and drug plans. In addition, this final rule expands the Medicare Diabetes Prevention Program model.


Subject(s)
Fee Schedules/economics , Fee Schedules/legislation & jurisprudence , Medicare Part B/economics , Medicare Part B/legislation & jurisprudence , Medicare Part C/economics , Medicare Part C/legislation & jurisprudence , Medicare Part D/economics , Medicare Part D/legislation & jurisprudence , Medicare/economics , Medicare/legislation & jurisprudence , Prospective Payment System/economics , Prospective Payment System/legislation & jurisprudence , Cost Savings , Diabetes Mellitus/economics , Diabetes Mellitus/prevention & control , Humans , United States
19.
Fed Regist ; 80(226): 73273-554, 2015 Nov 24.
Article in English | MEDLINE | ID: mdl-26606762

ABSTRACT

This final rule implements a new Medicare Part A and B payment model under section 1115A of the Social Security Act, called the Comprehensive Care for Joint Replacement (CJR) model, in which acute care hospitals in certain selected geographic areas will receive retrospective bundled payments for episodes of care for lower extremity joint replacement (LEJR) or reattachment of a lower extremity. All related care within 90 days of hospital discharge from the joint replacement procedure will be included in the episode of care. We believe this model will further our goals in improving the efficiency and quality of care for Medicare beneficiaries with these common medical procedures.


Subject(s)
Arthroplasty, Replacement/economics , Comprehensive Health Care/economics , Medicare Part A/economics , Medicare Part B/economics , Prospective Payment System/economics , Reimbursement Mechanisms/economics , Comprehensive Health Care/legislation & jurisprudence , Economics, Hospital/legislation & jurisprudence , Humans , Medicare Part A/legislation & jurisprudence , Medicare Part B/legislation & jurisprudence , Prospective Payment System/legislation & jurisprudence , Reimbursement Mechanisms/legislation & jurisprudence , United States
20.
Fed Regist ; 80(220): 70885-1386, 2015 Nov 16.
Article in English | MEDLINE | ID: mdl-26571548

ABSTRACT

This major final rule with comment period addresses changes to the physician fee schedule, and other Medicare Part B payment policies to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services, as well as changes in the statute.


Subject(s)
Fee Schedules/legislation & jurisprudence , Medicare Part B/economics , Medicare Part B/legislation & jurisprudence , Prospective Payment System/economics , Prospective Payment System/legislation & jurisprudence , Humans , Quality Indicators, Health Care/economics , Quality Indicators, Health Care/legislation & jurisprudence , Relative Value Scales , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...